Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Aimovig (erenumab) for the Treatment of Episodic Migraine

Drug (Brand/Generic)

Aimovig™ (erenumab)

Developers

Novartis and Amgen

Product Description

Selective calcitonin gene-related peptide (CGRP) antagonist

Therapy Class

Monoclonal antibody

Current Indication

Migraine

Market Sector

CNS

Development Status

Approved in the US
Expand

Go Top